• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제1권1호
• /
• pp.77-88
• /
• 1990

주의력 결핍장애아동의 치료는 악물치료가 중요하지만 중복장애아동과 같은 원칙에서 인지-행동적, 교육적 접근과 상호보완이 필요하다. 치료의 첫단계는 진단을 확립하고, 아동, 부모, 교사에게 이장애의 특성을 설명해 주고 치료의 대책을 세운다. 약물치료는 주로 중추신경자극제-그중에서도 메칠페니데이트를 중심으로 논의하였고, 그외에 삼환계 항우울제, 클로니딘, 항정신병약물이 소개되었다. 약물치료이외의 방법들로는 정신요법, 인지행동요법, 교육적 방법과 부모및 가족상담의 원칙들을 논의하였다. 이들 전통적인 치료방법이외에 논란되고 있는 식이요법, 비타민요법, 저당분요법, 미네랄요법, 정제된 당분의 투여, 신경학적 조직의 이론에 근거한 운동요법들을 소개하고 설명하였다.

• 생물정신의학
• /
• 제23권3호
• /
• pp.69-79
• /
• 2016

Frontotemporal dementia (FTD) is a degenerative disease characterized by the selective frontal and temporal lobe atrophy, and progressive deficits in behavior, executive function, or language. The prevalence and incidence of FTD are 15-22/100000 and 2.7-4.1/100000, respectively, in midlife. Hereditary is an important risk factor for FTD. Although there is some controversy regarding the further syndromatic subdivision of the different types of FTD, FTD is clinically classified into behavioral variant of frontotemporal dementia, semantic dementia and progressive nonfluent aphasia. FTD can be misdiagnosed as many psychiatric disorders because of similarity of the prominent behavioral features. Advances in clinical, imaging, and molecular characterization have increased the accuracy of FTD diagnosis, thus developing for the accurate differentiation of these syndromes from psychiatric disorders. We also discuss about therapeutic strategies for symptom management of FTD. Medications such as serotonin reuptake inhibitors, antipsychotics, and other novel treatments have been used in FTD with various rates of success. Further advanced research should be directed at understanding and developing new diagnostic and therapeutic modalities to improve the FTD patients' prognosis and quality of life.

• 대한의사협회지
• /
• 제61권12호
• /
• pp.758-764
• /
• 2018

Dementia is a clinical syndrome characterized by a cluster of symptoms and signs that manifest as difficulties in cognitive functions such as memory, psychological and psychiatric changes, and impairments in activities of daily living. As a result of worldwide trends of population aging, dementia has had a huge impact on public health in almost all countries. Disease modification therapies for dementia have not yet been developed. However, pharmacotherapy is essential in patients with dementia to combat delays in their cognitive and functional decline. In this article, we review the current pharmacotherapy for dementia. Three acetylcholinesterase inhibitors-donepezil, rivastigmine, galantamine-and memantine are the only medications that have been approved for the treatment of dementia. We present the indications, dose recommendations, side effects, and criteria for National Health Insurance coverage in Korea of these medications for dementia treatment. Although the Ministry of Food and Drug Safety in Korea has not approved any medications for managing the behavioral and psychological symptoms of dementia, some antipsychotics and antidepressants have been studied and used clinically for those purposes. Clinicians may consider vitamin E, Ginkgo biloba extract, choline alfoscerate, or omega-3 fatty acids as additional treatment options. Non-steroid anti-inflammatory drugs, estrogen hormone therapy, and statins are not generally recommended for dementia treatment. We believe that our findings will aid clinicians in the treatment of patients with cognitive decline.

• 대한조현병학회지
• /
• 제22권1호
• /
• pp.1-7
• /
• 2019

Objectives: Clozapine is the drug of choice in treatment-resistant schizophrenia. However, its use is often delayed and a significant proportion of clozapine treated patients fails to respond and experience potentially dangerous side-effects. The aim of this retrospective study was to describe the clinical characteristics of patients started on clozapine and the rate and reason of discontinuation of clozapine. Methods: Medical records of 83 patients started on clozapine during the period of 2012-2016 were reviewed. Results: Clozapine started on patients in chronic phase; the mean age of start was 38.1 years old and the mean number of psychiatric admission was 6.5. A majority (80.7%) of the patients had been subjected to antipsychotic polypharmacy prior to clozapine and most (61.5%) of them were being treated with polypharmacy including clozapine. Overall, 39 (47.0%) subjects had continued clozapine whereas 15 (18.1%) discontinued it; 29 (34.9%) were lost to follow-up. The most common reason for discontinuation was side-effects (n=13) including six life-threatening cases, most of which occurred within 6 months of its start. Conclusion: This study demonstrated that there is some evidence of delays to clozapine use, high rates of polypharmacy and significant rate of discontinuation during the early phase of clozapine treatment.

• 생물정신의학
• /
• 제10권2호
• /
• pp.177-185
• /
• 2003

Object:We investigated the relationship between prolactin response to antipsychotics and clinical courses of psychotic symptoms and DAT gene polymorphisms. Method:Twenty-four acute psychotic inpatients completed the 12-week trial of risperidone. Serum prolactin, BPRS, ESRS and hyperprolactinemia-related symptoms were measured at baseline, 2, 4, 8 and 12 weeks after medication. The DAT gene polymorphisms were analyzed. Results:The serum prolactin was significantly increased over time. According to the prolactin level at 2-week, the subjects were divided into the severe group(serum prolactin>60ng/mL, N=15) and the mild group (serum prolactin<60ng/mL, N=9). The prolactin levels of the mild group didn't increase beyond 60ng/mL throughout 12 weeks. Severe group had slower decrement of BPRS scores than those of mild group. Six females in severe group complained of irregular menstruations, but no female in mild group. Most patients had 10 allele of DAT gene. Conclusion:This study suggests that the magnitude of prolactin elevation at the 2-week of risperidone medication is correlated with severity of hyperprolactinemia throughout treatments. Our results did not show the relationship between prolactin responses and DAT gene polymorphisms.

• Biomolecules & Therapeutics
• /
• 제20권1호
• /
• pp.1-18
• /
• 2012

Schizophrenia is a devastating psychiatric illness that afflicts 1% of the population worldwide, resulting in substantial impact to patients, their families, and health care delivery systems. For many years, schizophrenia has been felt to be associated with dysregulated dopaminergic neurotransmission as a key feature of the pathophysiology of the illness. Although numerous studies point to dopaminergic abnormalities in schizophrenia, dopamine dysfunction cannot completely account for all of the symptoms seen in schizophrenia, and dopamine-based treatments are often inadequate and can be associated with serious side effects. More recently, converging lines of evidence have suggested that there are abnormalities of glutamate transmission in schizophrenia. Glutamatergic neurotransmission involves numerous molecules that facilitate glutamate release, receptor activation, glutamate reuptake, and other synaptic activities. Evidence for glutamatergic abnormalities in schizophrenia primarily has implicated the NMDA and AMPA subtypes of the glutamate receptor. The expression of these receptors and other molecules associated with glutamate neurotransmission has been systematically studied in the brain in schizophrenia. These studies have generally revealed region- and molecule-specifi c changes in glutamate receptor transcript and protein expression in this illness. Given that glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia, recent drug development efforts have targeted the glutamate system. Much effort to date has focused on modulation of the NMDA receptor, although more recently other glutamate receptors and transporters have been the targets of drug development. These efforts have been promising thus far, and ongoing efforts to develop additional drugs that modulate glutamatergic neurotransmission are underway that may hold the potential for novel classes of more effective treatments for this serious psychiatric illness.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제15권2호
• /
• pp.143-151
• /
• 2004

연구목적：소아·청소년기 발병 강박장애는 낮은 약물반응, 높은 공존장애율, 강한 유전적 경향성을 가진다고 알려져 왔다. 그러나 현재까지 국내에서 소아·청소년기 발병 강박장애에 대한 연구는 극히 미미하다. 이에 본 연구에서는 서울대학교병원 소아·청소년 정신과 병동에 입원한 강박장애 아동들을 대상으로 임상양상, 유전부하, 약물 반응양상, 퇴원후의 경과등을 조사하여, 심각한 증상을 보이는 소아·청소년 강박장애 군의 특성을 파악하려 하였다. 방 법：최근 9년사이에 서울대병원 소아·청소년 정신과에 입원한 환아 20명(남 16, 여 4)의 자료를 조사하였고 이를 대상으로 임상적 특성을 조사하였다. 진단 및 임상 상의 정확성을 유지하기 위해 의무기록지, 심리학적 보고서, 가족 면담 자료, 간호 보고서를 모두 고려하였고, 퇴원시 확정된 진단을 일차진단으로 하였다. 결 과：1) 환아의 성비는 남성이 4：1로 우위였다. 2) 강박사고에 있어서 가장 흔한 형태는 병적의심이었고, 이어서 더러움에 대한 공포, 공격적 사고, 대칭에의 요구, 성적 강박 사고였다. 강박행동에서 가장 흔한 내용은 확인, 씻기, 숨쉬기, 움직임, 대칭, 반복적 질문, 물건수집, 정신적 강박행동 등이었다. 3) 가장 흔한 공존 장애는 우울증이었고, 그 다음으로는 다른 불안장애, 틱장애, 품행장애, 반항장애였다. 드물게 강박사고에 대한 현실검증력이 손상된 것으로 판단되는 아동도 발견되었다. 4) 정신과 질환에 대한 가족력을 살펴본 결과, 17 가족(85%)에서 2차 친척 중 정신과 장애를 앓는 사람이 발견되었다. 그리고, 강박 스펙트럼 장애로 의심되는 친척을 둔 아동이 전체의 45%(9명)이었다. 5) 약물치료로서 사분의 삼 정도의 환아들(75%)이, SSRI와 항정신병약물을 함께 복용하고 있었고, 치료 반응상 CGI에서 중등도 호전(moderate improved) 이상을 보이는 경우가 75%로 파악되었다. 6) 퇴원 후의 외래 추적 결과, 지속적인 증상의 관해를 보인 경우는 5명(25%)이었고, 부분적인 증상을 가진 채 만성적으로 지속되는 경우가 10명(50%)이었다. 결 론：심각한 소아·청소년 강박장애약물 환아들의 임상상을 국내에서는 최초로 체계적으로 조사하였다. 그 결과, 높은 공존장애율, 높은 정신과장애의 가족력, 높은 항정신병약물 복용을 보이는 것으로 조사되었다. 증상면에서도 공격적-성적 강박사고의 비율이 높았으며, 숨쉬기, 움직이기 등의 특이한 강박행동이 발견되었다. 치료로서 사분의삼 정도의 환아들(75%)이, SSRI와 항정신병약물을 함께 복용하고 있었고, 치료 반응상 CGI에서 중등도 호전(moderate improved) 이상을 보이는 경우가 75%로 파악되었다.

• 생물정신의학
• /
• 제19권4호
• /
• pp.187-192
• /
• 2012

Objectives Although antipsychotic drug clozapine has superior efficacy, this is hampered by metabolic side effects such as weight gain and diabetes. Recent studies demonstrate that clozapine induces insulin resistance. However, the identity and location of insulin resistance induced by clozapine has not been clarified. In this study, the effect of clozapine on central insulin response was investigated in rats. Methods Male Sprague-Dawley rats received intraperitoneal injection of clozapine or vehicle, which was followed by intracerebroventricular injection of insulin or its vehicle. The effects of clozapine on insulin-induced changes in blood glucose level and Akt phosphorylation in hypothalamus were investigated. Results Intraperitoneal injection of clozapine (20 mg/kg) increased blood glucose in rats. Intracerebroventricular injection of insulin reduced blood glucose in rats, which was blunted by pretreatment of clozapine. Accompanied with the antagonistic effect of clozapine to central insulin action in terms of blood glucose, clozapine inhibited the insulin-induced phosphorylation of Akt at Ser473 in rat hypothalamus. Conclusion Administration of clozapine inhibited the central insulin-induced changes in blood glucose and Akt phosphorylation in rat hypothalamus. These findings suggest that hypothalamus could be the site of action for the clozapine-induced insulin resistance.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제4권1호
• /
• pp.27-38
• /
• 1993

전반적 발달장애는 가장 심각한 소아정신과 장애중 하나로 발달의 여러가지 영역에 있어 이상 소견을 보인다. 약물치료로 전반적 발달장애를 완치 할 수 없으며 치료효과 역시 비특이적이다. 그러나 일부의 전반적 발달장애 아동에게 약물치료는 매우 중요하기도 하고, 행동치료나 교육에 임하는 데에 있어 휠씬 도움을 줄 수 있다. 지금까지 가장 많이 연구된 항정신병 약물인 halopcridol은 임상적으로나 통계적으로 확실히 위약보다 훌륭한 효과를 보이고 있고, 약물의 부작용을 초래하지 않으면서 변별학습이나 모방적 언어사용등 긍정적인 기능을 촉진하는 것으로 보고되고 있다. 그러나 이러한 halopcridol의 투여는 약물과 관련된 운동장애를 초래할 수 있기 때문에 보다 안전한 다른 약물을 찾고자 하는 이유가 된다. 지금까지의 몇몇 생화학적인 연구들은 전반적 발달장애 아동의 일부에서 대조군에 비하석 혈중내 세로토닌치가 높거나, 내인성 opioid 측정치가 높은 군이 있을 것이라는 보고를 하고 있다. 이러한 소견을 근거로 하여 약물치료가 시도 되기도 하였는데, 예를들면, fenfluramine이나 naltrexone등이 그러하다. 그러나 아직 까지의 결과는 결론적이지 못하다. 이 약물들과 이 밖에도 지금까지 전반적 발달장애 아동에게 사용되어진 약물들과 그들의 효과에 대하여 고찰하고자 한다.

• 생물정신의학
• /
• 제5권1호
• /
• pp.114-121
• /
• 1998

Bethanechol, a cholinergic agonist, has been recommended for the management of peripheral anticholinergic side effects during the treatment of antipsychotic medications. But there have been few studies which have evaluated the drug interactions of antipsychotics and bethanechol, even the treatment effects of bethanechol on anticholinergic side effects. So the authors have evaluated whether psychopathology and plasma haloperidol and reduced haloperidol concentrations are significantly changed or not when bethanechol was administrated with maintained doses of haloperidol and other coadministrated drugs(such a benztropine). Also we have evaluated the abating effects of bethanechol on anticholinergic side effects during the treatment with haloperidol. Fifteen schizophrenics with higher than 5 of total score of anticholinergic side effects of 'Rating scale for side effect' were assigned to two groups, and bethanechol 30mg/day and 60mg/day were applied on each group for 4 weeks. The daily haloperidol dosages were fixed before 2 weeks of study. We assessed anticholinergic side effects by 'Rating scale for side effect' and psychopathology by BPRS, and plasma haloperidol and reduced haloperidol concentrations by HPLC at baseline, 2nd week and 4th week. The results were as followed, 1) there was no significant change of plasma haloperidol and reduced haloperidol concentration, 2) at baseline, the dosage of haloperidol showed significant correlation with the total score of anticholinergic side effect, but not at 2nd week and 4th week, 3) in 60mg/day group, dry mouth and the total score of anticholinergic side effects were significantly improved, but not in 30mg/day group, 4) there was no significant change of BPRS except withdrawal at 2nd week. These results suggest that coadministration of bethanechol influenced neither on psychopathology nor on plasma haloperidol and reduced haloperidol concentrations and that improved dry mouth and total score of anticholinergic side effects at 60mg/day.